Latest Venous ulcer Stories
A commitment to a healthy new year also means healthy veins. Dr.
FORT WORTH, Texas, Aug. 4, 2011 /PRNewswire/ -- Healthpoint Biotherapeutics today announced positive topline results for its Phase IIb clinical trial investigating the efficacy of HP802-247 in venous leg ulcers.
EDMONTON, June 29, 2011 /PRNewswire/ - Exciton Technologies Inc. today announced the Company has signed a distribution agreement with Marathon Medical, adding them to the existing Federal Supply Schedule (FSS) contract, administered by the Department of Veterans Affairs on behalf of the U.S.
FORT WORTH, Texas, May 11, 2011 /PRNewswire/ -- Healthpoint Biotherapeutics today announced the introduction of OASISÂ® Ultra Tri-Layer Matrix, a natural extracellular matrix (ECM) material derived from three layers of porcine small intestinal submucosa (SIS).
ROCKVILLE, Md., Nov. 24, 2010 /PRNewswire/ -- Glycotex, Inc., a clinical stage biopharmaceutical company, announced today that it has been awarded a cash grant totaling $244,479 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.
ADDISON, Texas, Nov. 10, 2010 /PRNewswire/ -- ULURU Inc.
CANTON, Mass., Sept. 28 /PRNewswire/ -- Organogenesis, Inc. announced that its ApligrafÂ® bilayered living cellular construct has been approved for the treatment of diabetic foot ulcers and other chronic wounds by the Saudi Food and Drug Authority (SFDA) of the Kingdom of Saudi Arabia.
ZUG, Switzerland and CANTON, Mass., May 26 /PRNewswire/ -- Organogenesis Switzerland GmbH will sponsor a symposium on ApligrafÂ®, a bilayered living cellular construct for the treatment of chronic wounds and soft tissue repair, at the upcoming European Wound Management Association (EWMA) conference.
- The parings of haberdine; also, any kind of fragments.